How many jobs is Novartis planning to cut in Basel, and what is the reason for the cuts?

Novartis could cut about 130 jobs in Switzerland as it relocates laboratory activities and shuts down some production in Basel. The job cuts stem from the planned transfer of laboratories for biological cell banks, analytical testing procedures, and technical development activities from Kleinbasel to its main campus in Basel by the end of 2028, as well as the cessation of small-scale biologics production in Kleinbasel by the end of 2027.

What is the timeline and scope of Novartis’s Kleinbasel site consolidation, and how does it relate to lease expirations?

Novartis plans to complete the relocation of laboratory activities from Kleinbasel to its main Basel campus by the end of 2028 and halt small-scale biologics production there by the end of 2027; this consolidation aligns with the expiration of individual leases at the Kleinbasel site in 2029 and is part of a previously announced plan—first disclosed in 2022—to establish a new biologics technical development centre on its main campus.

Novartis Could Cut About 130 Jobs in Basel Site Relocation

Sep 2, 2026

Novartis plans to relocate laboratory and biologics production activities from its Kleinbasel site to its main campus, potentially cutting around 130 jobs by 2028. The move aligns with lease expirations and supports broader investments in US manufacturing facilities.

reuters

2026-03-24

March 24 Business Watch: Helium Capacity Taken Out in Qatar; Novartis to Pay $2 Billion for Small Molecule

2026-05-05

Novartis to cut 220 jobs as it closes German site

2026-07-20

Novartis Backs Full-Year Forecast After Profit Beat Driven by One-Offs

2026-09-02

Novartis Could Cut About 130 Jobs in Basel Site Relocation

2026-09-07

Novartis falls as failed cholesterol drug study raises stakes for pipeline